References
- Wolber EM, Jelkmann W. Thrombopoietin: The novel hepatic hormone. News Physiol Sci 2002; 17: 6–10
- Weich NS, Wang A, Fitzgerald M, Neben TY, Donaldson D, Giannotti J, Yetz-Aldape J, Leven RM, Turner KJ. Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood 1997; 90: 3893–3902
- Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440–2452
- Zheng C, Yang R, Han Z, Zhou B, Liang L, Lu M. TPO independent megakaryopoiesis. Crit Rev Oncol Hematol 2008; 65: 212–222
- Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 2001; 98: 2720–2725
- Eaton DL, de Sauvage FJ. Thrombopoietin: The primary regulator of megakaryopoiesis and thrombopoiesis. Exp Hematol 1997; 25: 1–7
- Geissler K, Valent P, Bettelheim P, Sillaber C, Wagner B, Kyrle P, Hinterberger W, Lechner K, Liehl E, Mayer P. In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 1992; 79: 1155–1160
- Stahl CP, Zucker-Franklin D, Evatt BL, Winton EF. Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood 1991; 78: 1467–1475
- Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006; 134: 453–466
- Usuki K, Tahara T, Iki S, Endo M, Osawa M, Kitazume K, Kato T, Miyazaki H, Urabe A. Serum thrombopoietin level in various hematological diseases. Stem Cells 1996; 14: 558–565
- Weisdorf DJ, DeFor T, Nichol J, Panoskaltsis-Mortari A, Blazar BR. Thrombopoietic cytokines in relation to platelet recovery after bone marrow transplantation. Bone Marrow Transpl 2000; 25: 711–715
- Folman CC, Jong CM, de Haas M, von dem Borne AE. In multiple myeloma increased thrombopoietin (TPO) production may be involved in the maintenance of platelet production. Eur J Haematol 2001; 66: 337–341
- Fritz E, Ludwig H, Scheithauer W, Sinzinger H. Shortened platelet half-life in multiple myeloma. Blood. 1986; 68: 514–520
- Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854
- Kyle R. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 347–358
- Heitz F, Stahl M, Ludwig D, Stange EF, Jelkmann W. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombopoiesis associated with inflammatory bowel disease. J Interferon Cytokine Res 1999; 19: 757–760
- Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B. Biologic effect of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685–691
- Kaushansky K. Historical review: Megakaryopoiesis and thrombopoiesis. Blood 2008; 111: 981–986
- Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106(12)3777–3784